Navigation Links
Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia
Date:4/20/2009

Cardio-diagnostic company adds new line of heart disease and diabetes tests to complement advanced cholesterol profile

BIRMINGHAM, Ala., April 20 /PRNewswire/ -- Atherotech, Inc. today announced it will be exhibiting its VAP(R) Cholesterol Test in booth #912 at Internal Medicine 2009, the annual scientific meeting of the American College of Physicians (ACP). The conference takes place April 23-25, 2009, at the Pennsylvania Convention Center in Philadelphia.

Used in more than 100 clinical trials, including the Heredity and Phenotype Intervention (HAPI) Heart Study recently published in Science, the VAP (Vertical Auto Profile) Test is the most accurate cholesterol test available today.

The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard test and can identify a far great number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The test identifies markers for metabolic syndrome, a precursor for diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

The VAP Test provides physicians and researchers with direct measurement of LDL, HDL and all relevant subclasses, non-HDL and emerging risk factors such as Lp(a), remnants and small dense LDL.

Atherotech recently announced the addition of more than a dozen tests for patients at intermediate to high risk of cardiometabolic diseases. The new test panels are available immediately and also include homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D, fibrinogen and insulin. The tests can be ordered individually, or bundled as part of a custom risk profile that may also include the VAP Test.

Atherotech representatives will be available to discuss the VAP Cholesterol Test and its line of cardiovascular assays in booth #912, and blood draws will be provided to qualified attendees during exhibit hours April 23-25. Because LDL is directly measured, fasting is not required. Test results will be returned via mail after the conference.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with triglycerides > 150, HDL < 40, LDL >130, total cholesterol > 200) should also opt for the more detailed VAP Test.

The VAP Test is available nationwide and is covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
8. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
9. Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
10. Atherotech Unveils New Cardiometabolic Test Panels
11. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... ; Frankfurt Prime Standard: QIA) today announced the introduction ... for gene expression profiling, expanding QIAGEN,s portfolio of Sample ... enable researchers to select from over 20,000 human genes ... interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
Breaking Biology News(10 mins):